Autologous transplantation of muscle-derived CD133+ cells was then successfully performed in phase I clinical trial involving eight DMD boys that assured treatment safety and some degree of improvement in markers of skeletal muscle function [130]. Here, PROM1 is linked to Duchenne muscular dystrophy.